X0202 SCHEDULE 13G/A 0001831942-25-000022 0001831942 XXXXXXXX LIVE 1 Common Stock, par value $0.01 per share 03/31/2026 0001357459 PALISADE BIO, INC. 696389402 4600 South Syracuse Street Suite 900 Denver CO 80237 Rule 13d-1(c) Commodore Capital LP DE 0.00 12366776.00 0.00 12366776.00 12366776.00 7.2 IA PN Commodore Capital Master LP E9 0.00 12366776.00 0.00 12366776.00 12366776.00 7.2 PN Robert Egen Atkinson X1 0.00 12366776.00 0.00 12366776.00 12366776.00 7.2 HC IN Michael Kramarz X1 0.00 12366776.00 0.00 12366776.00 12366776.00 7.2 HC IN PALISADE BIO, INC. 4600 South Syracuse Street, Suite 900, Denver, COLORADO, 80237. Commodore Capital LP Commodore Capital Master LP Robert Egen Atkinson Michael Kramarz Each a "Filer." The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. See Item 4 of the cover page for each Filer. Y See Item 9 of the cover page for each Filer. This report on Schedule 13G is being filed by Commodore Capital LP (the "Firm"), Commodore Capital Master LP ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of March 31, 2026, the Firm may be deemed to beneficially own an aggregate of 12,366,776.00 shares of Common Stock, par value $0.01 per share (the "Common Stock"), consisting of (i) 7,181,062 shares of the Common Stock and (ii) 5,185,714 shares of Common Stock each Filer has the right to acquire through the exercise of a pre-funded warrant ("Pre-Funded Warrant") of Palisade Bio, Inc. (the "Issuer"), which is subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation"). The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 167,421,702 Common Stock reported as issued and outstanding as of March 31, 2026 in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, plus 5,185,714 shares of Common Stock which the Filers may acquire upon the exercise of the Pre-Funded Warrant, subject to the Beneficial Ownership Limitation. See Item 11 of the cover page for each Filer. See Item 5 of the cover page for each Filer. See Item 6 of the cover page for each Filer. See Item 7 of the cover page for each Filer. See Item 8 of the cover page for each Filer. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1: Joint Filing Agreement Commodore Capital LP Michael Kramarz 05/15/2026 Commodore Capital Master LP Michael Kramarz 05/15/2026 Robert Egen Atkinson Robert Egen Atkinson 05/15/2026 Michael Kramarz Michael Kramarz 05/15/2026